Paper33332777
The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells.
Hwang HJ and 9 others. Immun Inflamm Dis, 2021. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells. Papers, record 33332777. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33332777
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Programmed Cell Death 1 Receptor | Major topic |
| T-Lymphocytes | Major topic |
| Cell Proliferation | |
| Humans | |
| Receptors, Immunologic | |
| Signal Transduction |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U51 IP000837 | NCIRD CDC HHS | United States | U51IP000837 | PubMed and NIH | NIH RePORTER |
| R43 IP000002 | NCIRD CDC HHS | United States | R43IP000002 | PubMed and NIH | NIH RePORTER |
References45
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27974689 | PD-1 and its ligands are important immune checkpoints in cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/27974689 | PubMed |
| 2 | 26086965 | T-cell exhaustion in the tumor microenvironment. | Cell Death Dis | 2015 | https://conductscience.org/library/papers/26086965 | PubMed |
| 3 | 22467661 | Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. | J Immunol | 2012 | https://conductscience.org/library/papers/22467661 | PubMed |
| 4 | 23470321 | Molecular mechanisms of T cell co-stimulation and co-inhibition. | Nat Rev Immunol | 2013 | https://conductscience.org/library/papers/23470321 | PubMed |
| 5 | 11015443 | Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. | J Exp Med | 2000 | https://conductscience.org/library/papers/11015443 | PubMed |
| 6 | 25220446 | Targeted activation of human Vγ9Vδ2-T cells controls epstein-barr virus-induced B cell lymphoproliferative disease. | Cancer Cell | 2014 | https://conductscience.org/library/papers/25220446 | PubMed |
| 7 | 31963646 | Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/31963646 | PubMed |
| 8 | 21268005 | Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens. | Eur J Immunol | 2011 | https://conductscience.org/library/papers/21268005 | PubMed |
| 9 | 31570447 | Expression of Immune Checkpoint Receptors on T-Cells and Their Ligands on Leukemia Blasts in Childhood Acute Leukemia. | Anticancer Res | 2019 | https://conductscience.org/library/papers/31570447 | PubMed |
| 10 | 29971847 | Depletion of αβ+ T cells for a haploidentical hematopoietic stem cell transplantation in children. | J Clin Apher | 2018 | https://conductscience.org/library/papers/29971847 | PubMed |
| 11 | 28344861 | Zoledronic acid boosts γδ T-cell activity in children receiving αβ+ T and CD19+ cell-depleted grafts from an HLA-haplo-identical donor. | Oncoimmunology | 2017 | https://conductscience.org/library/papers/28344861 | PubMed |
| 12 | 25665048 | Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies. | Bone Marrow Transplant | 2015 | https://conductscience.org/library/papers/25665048 | PubMed |
| 13 | 22437939 | Adoptive immunotherapy for cancer: harnessing the T cell response. | Nat Rev Immunol | 2012 | https://conductscience.org/library/papers/22437939 | PubMed |
| 14 | 32437509 | PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. | J Cell Biol | 2020 | https://conductscience.org/library/papers/32437509 | PubMed |
| 15 | 16870417 | Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. | Curr Opin Immunol | 2006 | https://conductscience.org/library/papers/16870417 | PubMed |
| 16 | 24091816 | Phenotype and regulation of immunosuppressive Vδ2-expressing γδ T cells. | Cell Mol Life Sci | 2014 | https://conductscience.org/library/papers/24091816 | PubMed |
| 17 | 31488176 | Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. | J Hematol Oncol | 2019 | https://conductscience.org/library/papers/31488176 | PubMed |
| 18 | 24315996 | The inhibitory receptor BTLA controls γδ T cell homeostasis and inflammatory responses. | Immunity | 2013 | https://conductscience.org/library/papers/24315996 | PubMed |
| 19 | 23761635 | CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. | J Immunol | 2013 | https://conductscience.org/library/papers/23761635 | PubMed |
| 20 | 12796776 | BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. | Nat Immunol | 2003 | https://conductscience.org/library/papers/12796776 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42638743 | The BTLA/HVEM axis as a key regulator for stratified functional cure in chronic hepatitis B. | Front Immunol | 2026 | https://conductscience.org/library/papers/42638743 | PubMed |
| 41939883 | Revisiting the past in light of current knowledge on γδ T cells in leishmaniasis. | Front Immunol | 2026 | https://conductscience.org/library/papers/41939883 | PubMed |
| 41486149 | Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications. | J Biomed Sci | 2026 | https://conductscience.org/library/papers/41486149 | PubMed |
| 39348473 | Research Progress of γδT Cells in Tumor Immunotherapy. | Cancer Control | 2024 | https://conductscience.org/library/papers/39348473 | PubMed |
| 38858763 | γδ T cells and the PD-1/PD-L1 axis: a love-hate relationship in the tumor microenvironment. | J Transl Med | 2024 | https://conductscience.org/library/papers/38858763 | PubMed |
| 38375329 | Effective γδ T-cell clinical therapies: current limitations and future perspectives for cancer immunotherapy. | Clin Transl Immunology | 2024 | https://conductscience.org/library/papers/38375329 | PubMed |
| 37041226 | BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/37041226 | PubMed |
| 36793048 | Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. | Mol Cancer | 2023 | https://conductscience.org/library/papers/36793048 | PubMed |
| 36713444 | Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy. | Front Immunol | 2022 | https://conductscience.org/library/papers/36713444 | PubMed |
| 36140182 | The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition. | Biomedicines | 2022 | https://conductscience.org/library/papers/36140182 | PubMed |
| 36123348 | Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/36123348 | PubMed |
| 35406483 | Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35406483 | PubMed |
| 35203309 | The Mysterious Actor-γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL). | Cells | 2022 | https://conductscience.org/library/papers/35203309 | PubMed |
| 35127555 | Properties and Roles of γδT Cells in Plasmodium yoelii nigeriensis NSM Infected C57BL/6 Mice. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/35127555 | PubMed |
| 34572874 | Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34572874 | PubMed |
| 33332777 | The BTLA and PD-1 signaling pathways independently regulate the proliferation and cytotoxicity of human peripheral blood γδ T cells. | Immun Inflamm Dis | 2021 | https://conductscience.org/library/papers/33332777 | PubMed |
Genes22
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33332777
GET https://conductscience.org/api/papers/v1/33332777/references?page=2